share_log

Ardelyx | 8-K: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

Ardelyx | 8-K: Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

Ardelyx | 8-K:Ardelyx 公佈2024年第一季度財務業績並提供業務最新情況
美股sec公告 ·  05/02 16:10
Moomoo AI 已提取核心訊息
On May 2, 2024, Ardelyx, Inc., a biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced substantial revenue growth, driven by its two main products, IBSRELA and XPHOZAH. Ardelyx recorded $45.6 million in product-related revenue for the quarter, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended the quarter with approximately $203 million in cash and investments. The financial report highlighted significant year-over-year growth and the successful commercial performance of both products. Ardelyx expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million. The company also announced the appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy. Total revenue for the quarter was $46.0 million...Show More
On May 2, 2024, Ardelyx, Inc., a biopharmaceutical company, reported its financial results for the first quarter ending March 31, 2024. The company announced substantial revenue growth, driven by its two main products, IBSRELA and XPHOZAH. Ardelyx recorded $45.6 million in product-related revenue for the quarter, with $28.4 million from IBSRELA and $15.2 million from XPHOZAH. The company ended the quarter with approximately $203 million in cash and investments. The financial report highlighted significant year-over-year growth and the successful commercial performance of both products. Ardelyx expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million. The company also announced the appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy. Total revenue for the quarter was $46.0 million, compared to $11.4 million in the same period of 2023. Research and development expenses were $10.6 million, and selling, general and administrative expenses were $53.0 million. The net loss for the quarter was $26.5 million, or $(0.11) per share. The company also provided important safety information for IBSRELA and XPHOZAH, highlighting the risk of serious dehydration in pediatric patients and contraindications in certain individuals.
2024年5月2日,生物製藥公司Ardelyx, Inc. 公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈收入大幅增長,這得益於其兩大主要產品IBSRELA和XPHOZAH。Ardelyx在本季度創下了4560萬美元的產品相關收入,其中2,840萬美元來自IBSRELA,1,520萬美元來自XPHOZAH。該公司在本季度末擁有約2.03億美元的現金和投資。財務報告強調了這兩種產品的顯著同比增長以及成功的商業表現。Ardelyx預計,IBSRELA2024年全年美國的淨產品銷售收入將在1.4億美元至1.50億美元之間。該公司還宣佈任命邁克·凱利赫爲企業發展和戰略執行副總裁。該季度的...展開全部
2024年5月2日,生物製藥公司Ardelyx, Inc. 公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈收入大幅增長,這得益於其兩大主要產品IBSRELA和XPHOZAH。Ardelyx在本季度創下了4560萬美元的產品相關收入,其中2,840萬美元來自IBSRELA,1,520萬美元來自XPHOZAH。該公司在本季度末擁有約2.03億美元的現金和投資。財務報告強調了這兩種產品的顯著同比增長以及成功的商業表現。Ardelyx預計,IBSRELA2024年全年美國的淨產品銷售收入將在1.4億美元至1.50億美元之間。該公司還宣佈任命邁克·凱利赫爲企業發展和戰略執行副總裁。該季度的總收入爲4,600萬美元,而2023年同期爲1140萬美元。研發費用爲1,060萬美元,銷售、一般和管理費用爲5,300萬美元。該季度的淨虧損爲2650萬美元,合每股虧損0.11美元。該公司還爲IBSRELA和XPHOZAH提供了重要的安全信息,重點介紹了兒科患者嚴重脫水的風險和某些人的禁忌症。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息